Abstract
Therapy for cystic fibrosis (CF) has progressed during the past several decades. Much of this progress is because of advances in genetic testing to precisely identify the underlying cause of CF transmembrane regulator (CFTR) dysfunction. However, with more than 1900 mutations that can produce a faulty CFTR, the management of CF can remain a challenge. Several innovative drugs recently approved by the Food and Drug Administration, termed genetic modulators, target the underlying disease by modulating the CFTR defect. This review provides physicians with an established simple classification scheme to guide their use of these drugs. The treatment challenge of 1900 CFTR mutations has been simplified into 6 physiologic classes, each paired with an available therapy to offer patients the most functional improvement. Drug therapy monitoring, adverse effects, and indications for discontinuation must also be considered.
Cystic fibrosis (CF) is an autosomal recessive disease affecting more than 30,000 individuals in the United States and approximately 70,000 individuals worldwide.
1-4 It is most common in white persons, specifically Europeans and those with Ashkenazi Jewish ancestry.
5 It affects 1 in 3,000 live births among white persons and 1 in 17,000 live births among African American persons; it is rarely present in Native American or Asian populations.
2,5 The life expectancy during the 1960’s did not surpass the single digits.
6 With antibiotic and symptomatic intervention now available for CF patients at an early age, the life expectancy for an individual with CF has increased substantially; in 2013, predicted median survival was reported to be 41 years.
1 Unfortunately, no cure exists for CF, and, until recently, therapies have been directed only at its associated symptoms and complications.
The central theme to CF is an absent or dysfunctional CF transmembrane regulator (CFTR), a vital chloride ion transporter in multiple organs that controls the regulation of epithelial sodium transport. A diseased CFTR leads to dilatation of exocrine glands (from mucus obstruction and thick, productive mucopurulent secretions) accompanied by submucosal glandular hyperplasia. The result is multiorgan damage caused by ion, pH, and fluid imbalances.
2,7 Many patients present at birth with meconium ileus and pancreatic insufficiency due to small-bowel and pancreatic mucus obstruction, respectively.
2 In the pulmonary system, chloride ion and fluid imbalance lead to destruction of respiratory cilia, thick mucus collection in the distal airways, and, inevitably, progressive obstructive lung disease. Bacterial colonization of the respiratory tract, most notably from
Pseudomonas aeruginosa,
Burkholderia cepacia, and
Staphylococcus aureus, is a major cause of disease and death associated with chronic pulmonary infections.
As of 2011, more than 1900 mutations have been identified that may clinically manifest as CF, and approximately 1 in 25 white persons are carriers of a CF genetic mutation (though most who are heterozygous for these mutations do not present with CF).
8 These mutations compromise the integrity of the CFTR protein located on the outer membrane of epithelial cells.
8 Therefore, the most important organ systems affected by CF are those in which fluid and electrolyte balance by epithelial cells is critical, such as the airways, exocrine glands of the pancreas, bile ducts, and sweat glands.
A classification system
9 was devised and classifed in 6 classes based on molecular mechanisms and consequences that the mutation causes (
Table 1), which are as follows: no synthesis of CFTR (class I), premature degradation (class II), dysregulation (class III), abnormal conductance (class IV), decreased production (class V), and membrane instability (class VI).
2,7,8,10,11 Recent therapies have shifted toward treating classes of
CFTR mutations rather than allele-specific mutations.
11 This classification has become useful outside the research community and pharmaceutical industry because individual therapies are effective only in patients with a particular class of
CFTR mutation.
A major challenge in managing CF is the need to tailor individualized therapy for nearly every patient based on his or her genomic mutation. With several new therapies developed for these mutations, a shift toward managing the underlying disease rather than just managing symptoms is currently underway. Ivacaftor (VX-770) was the first of these genetic modulators to be approved by the US Food and Drug Administration (FDA), for the treatment of patients with a class III defect. Several other therapies have since been introduced for the clinical management of CF. In this review, we provide an overview of the genetic modulators currently available, using the classification system for defects to organize treatment options. We also describe several new drugs designed to correct the underlying genetic mutations in CF.
Class I defects account for single point mutations in DNA that inappropriately place a stop codon in the CFTR messenger RNA (mRNA) transcript and terminate the process of translation. The CFTR protein is left truncated, resulting in a loss of function at the apical layer of epithelial cells. These mutations are present in approximately 10% of patients with CF worldwide, and several novel therapies have been developed to target this specific population.
11
Tobramycin (Tobi; Novartis) is the bactericidal aminoglycoside antibiotic most commonly used today for coverage against severe gram-negative respiratory infections (eg,
P aeruginosa infection) in patients with CF.
13 Its mechanism is to interfere with bacterial proteins by binding to the 30S ribosomal RNA subunit during protein translation. Recent evidence suggests that aminoglycoside antibiotics can suppress premature termination codons by disrupting translational fdelity and allowing translation to continue to the normal termination of the transcript.
13 Aminoglycosides have additional dose-dependent pleiotropic effects whereby they induce “read-through” of premature stop codons, suppressing a premature stop codon and restoring synthesis to a full-length and functional CFTR protein.
14,15 Aminoglycoside binding to the ribosome enables read-through inducing misinterpretation of a stop codon, so that ultimately the stop codon directive is “ignored.”
16,17
Gentamicin was the first aminoglycoside investigated for this function.
14,15 Ex vivo administration of gentamicin was shown to increase CFTR function. In 2003, a double-blind, placebo-controlled trial
12 evaluated the use of topical nasal drops (gentamicin dose, 900 µg/d) to improve nasal respiratory function. This application significantly reduced the basal potential difference of nasal epithelium in both homozygous and heterozygous patients (n=19) with a stop codon defect (
P=.005).
7,12 Homozygous carriers of a nonsense mutation had a greater response to gentamicin, with apical CFTR function fully restored to nasal epithelial tissue in approximately 90% of patients. However, the high dosage needed to produce a clinically significant effect on chloride transport during systemic administration was a major limitation to the use of gentamicin (and other aminoglycosides). Although gentamicin has the pharmacologic potential to resolve several issues in CF, the required therapeutic dose has many toxic effects associated with long-term use, most notably renal and otovestibular effects.
11,12
At this publication, gentamicin and other amino-glycosides are not approved by the FDA for the sole purpose of CFTR modulation. However, many individuals with CF are treated with aminoglycosides (specifically tobramycin) for gram-negative pulmonary infections and not solely for modification of mutations.
13 Many physicians consider tobramycin the aminoglycoside of choice for managing lung infections associated with CF, with its pleiotropic effect in promoting CFTR modulation. We recommend using standard aminoglycoside dosing practices to manage the lung infections associated with CF, along with monitoring for renal toxic effects.
Ataluren (PTC 124; PTC Therapeutics),
18 currently recognized as an orphan drug by the FDA, is a more appealing therapeutic option for class I CFTR defects. In a mechanism similar to the pleiotropic effects of aminoglycosides, ataluren allows ribosomes to read through the mRNA premature stop codons, resulting in the translation of complete CFTR proteins.
19,20 Several phase II and III studies
19-21 have evaluated this drug’s efficacy and demonstrated improvements in nasal transepithelial potential differences, forced expiratory volume in 1 second (FEV
1), and weight gain in both adult and pediatric patient populations.
20 Adverse effects were generally mild, with gastrointestinal upset, headache, and dizziness most commonly reported (
Table 2). Because of its efficacy in targeting the underlying cause of CF and favorable adverse effect profile, ataluren is considered the more appropriate initial approach compared with aminoglycosides in patients with CF who have class I mutations.
10,21 Several phase III trials of ataluren are currently underway in patients with CF who are aged 6 years or older, to determine long-term safety and efficacy (
Table 3).
1,20 One phase III trial found that combining ataluren with tobramycin may reduce its efficacy, suggesting that this combination should not be used.
22 Another antibiotic would therefore need to replace tobramycin should a gram-negative infection develop in a patient receiving ataluren. In these situations, ideal antibiotic therapy would be based on culture and sensitivity results.
Class II defects of CFTR are present in 90% of all patients with CF (
Table 1). Patients with class II defects have a deletion of the amino acid phenylalanine at the 508 position (ΔF508), resulting in immature synthesis of the CF channel protein. The CFTR is only partially glycosylated and subsequently not released correctly from the endoplasmic reticulum. The structural errors are then recognized by the ubiquitin-proteasome system, and the abnormal CFTR protein is eventually degraded.
10 To counteract this error, lumacaftor (VX-809; Vertex Pharmaceuticals; phase II trials complete)
23-26 modulates function to ΔF508-
CFTR mutations by restoring the posttranslational modification at the endoplasmic reticulum. By avoiding degradation from ubiquitin and enhancing chloride ion secretion in bronchial epithelial cells, lumacaftor helps correct a ΔF508 mutation in patients with a class II defect and has been shown to increase CFTR chloride transport by 15% above baseline.
23-26
Measurement of sweat chloride concentrations in a randomized, double-blind, placebo-controlled trial
25 demonstrated statistically significant (
P=.0013) and sustained improvements in patients taking lumacaftor; these effects were dose dependent, with reductions of 6.1 and 8.2 mmol/L in sweat chloride concentrations after 28 days of therapy with daily lumacaftor doses of 100 mg and 200 mg, respectively. After discontinuation of the drug, however, this effect was rapidly reversed, suggesting that lumacaftor is bioactive and should be therapeutically maintained for an adequate clinical effect.
25 Additional research is currently underway to evaluate bioactivity and dosing regimens, because no ideal regimen has yet been established. Results reported for varying doses suggest that no significant difference has been found in adverse effects between therapeutic and placebo groups (
Table 4); the most common adverse effects were headache and cough, with 4 of 89 patients (5%) in 1 study reporting severe pulmonary adverse effects that warranted discontinuation of the drug.
25
Normal CFTR function requires the recognition of adenosine triphosphate or cyclic adenosine monophosphate at the CFTR channel. Class III defects occur when this detection is absent.
5 The most common mutation that underlies this defect is a missense mutation of the amino acid glycine for aspartate at the 551 position (G551D) on the CFTR protein.
5 Potentiators amplify ion function by increasing the time that CFTR channels at the cell surface remain open, thereby addressing the class III defect.
2,3 The resultant downstream effect increases both the apical fluid height of epithelium and the ciliary beat frequency to restore function to a defective cilia transport system in epithelial cells, most notably in the respiratory tract. Ivacaftor (VX-770; Kalydeco–Vertex Pharmaceuticals) has been approved by the FDA as a CFTR potentiator for G551D
CFTR gating mutations, as well as many other gating mutations in patients aged 6 years or older (
Table 5).
27-29
In a randomized, double-blind, placebo-controlled trial
26 of ivacaftor, 84 patients aged 12 years or older with at least 1 G551D
CFTR mutation and an FEV
1 of 40% to 90% were treated with ivacaftor for 48 weeks. After 24 weeks, the predicted FEV
1 values of patients in the ivacaftor group showed absolute increases from baseline of 10.4% vs absolute decrease of 0.2% for the placebo group. Thus, the treatment effect was 10.6% corresponding with an increase in FEV
1 of 367 mL. These findings corresponded to a 10-fold increase in CFTR-mediated chloride transport in patients with CF and G551D mutations.
29 At the end of the study, patients treated with ivacaftor were 55% less likely to have a pulmonary exacerbation. Respiratory symptoms scored in a CF questionnaire were 8.6 points higher (ie, improved function) (score changes of >4 points were considered clinically significant) in the treatment group than in the placebo group, and treated patients had an average weight gain of 2.7 kg (5.94 lb) more than those treated with placebo. Most notably, ivacaftor was the first therapeutic agent to reduce sweat chloride levels below diagnostic thresholds (60 mmol/L), with these concentrations decreasing by a mean of 48.1 mmol/L in treated patients with G551D
CFTR mutations, a change correlated with clinical outcome (eg, lung function).
27,31
The ivacaftor group in that study had a lower proportion of serious adverse events (24% vs 48% in patients receiving placebo); the most common adverse effects were headache, oropharyngeal pain, and upper respiratory tract infections (
Table 5).
27,28 Ivacaftor is metabolized via the cytochrome P450 3A system into 2 metabolites: a slightly active one (one-sixth the potency of its parent compound) and an inactive one with 88% eliminated by fecal excretion. Because elevated levels of liver function enzymes have been noted, it has been recommended to screen for elevated aspartate aminotransferase and alanine aminotransferase levels before initiating treatment, every 3 months during the first year of treatment, and annually thereafter; elevated levels do not necessarily mean that ivacaftor should be discontinued, but levels should be monitored. Animal studies have shown that ivacaftor does cross the placenta, but no adequate human studies of effects on pregnant women are available, placing the current pregnancy classification as category B.
28
Studies are also currently underway to evaluate combination therapy. Several phase II trials have demonstrated improvements in FEV
1 and up to a 2-fold reduction in sweat chloride with lumicaftor/ivacaftor combination therapy compared with lumicaftor alone.
24 The results of the TRAFFIC and TRANSPORT trails that studied Lumacaftor in combination with Ivacaftor in patients 12 years of age or older who are homozygous for ΔF508-
CFTR mutation showed percent predicted FEV
1 improvement ranging from 2.6% to 4.0% (
P≤.001) from baseline compared to placebo with improvements sustained over 24 weeks.
32 There was a mean relative improvement for the Lumacaftor/Ivacaftor treatment group of 4.3% to 6.7% (
P≤.001) compared with placebo (
P<.001). In vitro research has shown that when lumacaftor and ivacaftor are used in combination, the chloride transport increases to 30%.
26 The most common adverse events reported were infective pulmonary exacerbations, cough, headache, and increased sputum, but the combination therapy was generally well tolerated (
Table 6).
33 Phase III trials are currently planned to evaluate dosing regimens for peak efficacy.
20
Other class III genetic modulators currently being evaluated include VX-661 (Vertex Pharmaceuticals), N6022 (N30 Pharmaceuticals), and C18 (another class III CFTR corrector under investigation). A study
34 evaluating the effects of lumacaftor and C18 therapy on the ΔF508 mutation has found that this combination can both enhance activation of ΔF508-CFTR and correct the associated folding defect. A phase II study evaluating VX-661 both alone and in combination with ivacaftor is still underway.
35 Other pending studies aim to increase effectiveness with drugs such as N6022 or drug combinations (lumacaftor with ivacaftor or VX-661), without increasing adverse effects.
24,35
Mutations to the
CFTR gene that involve low function, low production, or membrane instability (class IV, V, and VI defects, respectively) are seen in less than 10% of patients with CF.
9 Most research on CFTR modulation therapy has targeted gene mutations most commonly seen in clinical practice, with research in other classes neglected.
Class IV defects produce an abnormal CFTR protein at the outer membrane of epithelial cells, in which the gating/chloride channels do not function properly. In an experimental phase III study to evaluate its efficacy in patients with CF with the R117H-
CFTR mutation, ivacaftor improved CFTR channel function and lung function, reduced pulmonary exacerbations and respiratory symptoms, and increased weight gain; it was also well tolerated.
36
Class V defects have a functional CFTR present, but a splicing defect of mRNA results in a variable phenotype. The severity of disease in patients with class V defects has been postulated to be inversely related to the level of correctly spliced transcripts. Effective therapies would probably include a method to increase mRNA expression, and several compounds are currently under early investigation.
10
In the past 15 years, evidence has suggested that membrane conductance defects caused by ions other than chloride may also potentiate CFTR dysfunction by leading to membrane instability (class VI defects).
11,37 Truncation of the C-terminus of the primary CFTR protein structure may trigger this mechanism and has been a target of several therapies; however, little clinical evidence has supported this approach.
11
The standards for managing CF have changed considerably during the past 2 decades. Current therapies target the underlying disease by modulating CFTR mutations, which are divided into 6 categories (classes): no synthesis (I), premature degradation (II), dysregulation (III), abnormal conductance (IV), decreased production (V), and membrane instability (VI). Recommendations on CFTR modulation therapy for CF have remained elusive for several years despite continuing pharmacotherapeutic advances. This challenge is due in part to the large number of mutations that can lead to CF. Further research is needed in patients of different ethnicities and races to support a comprehensive understanding of the effects of treatment.
Practicing physicians today can use a small but growing number of drugs to treat patients with CF, but some proposed drugs are not readily available. We recommend that any individuals with a diagnosis of CF be considered candidates for genetic testing to determine which CFTR mutation underlies their disease. This information can then be used to categorize the mutation into a particular drug class (in classes I through VI) and determine the best therapeutic option to maximize functional improvement.
Drs Virant-Young, Thomas, and Woiderski, and Ms Powers provided substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; all authors drafted the article or revised it critically for important intellectual content; all authors gave final approval of the version of the article to be published; and all authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.